Improving Access to Care for Veterans With Memory Loss | NCT07117162 | Trialant

Improving Access to Care for Veterans With Memory Loss | NCT07117162 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
ADRD Care Delivery Protocol	Experimental	Patients will undergo telehealth preparedness assessment, cognitive screening, and blood biomarker testing prior to the initial consultation with the specialist.	Other: ADRD Care Delivery Protocol
Usual Care	No Intervention	Patients will undergo usual care with all evaluation and testing at the discretion of the specialist.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Time to Eligibility Determination	Compare the number of days from randomization to the determination of eligibility for monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.	From date of randomization until the date of determination of eligibility for monoclonal antibody therapy, assessed up to 12 months.
Time to Initial Infusion	Compare the number of days from the date of randomization to the initial infusion of monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.	From date of randomization until the date of first infusion, assessed up to 12 months.

Secondary Outcomes

Measure	Description	Time Frame
Number of Participants and Instances of Additional testing	Chart review will be used to determine the number of participants who underwent additional testing and the total number of additional tests performed. This includes counting instances of APOE genetic testing, MRI brain imaging, and amyloid PET imaging as ordered at the discretion of the specialist.	1 year

Contacts/Locations Module

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
	Background	DONANEMAB-AZBT INJ,SOLN - VA Formulary Advisor. Accessed December 12, 2024. https://www.va.gov/formularyadvisor/drugs/4043274-DONANEMAB-AZBT-INJ-SOLN
	Background	LECANEMAB-IRMB INJ,SOLN - VA Formulary Advisor. Accessed December 12, 2024. https://www.va.gov/formularyadvisor/drugs/4041980-LECANEMAB-IRMB-INJ-SOLN
37459141	Background	Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
33720637

Condition Browse Module